SCHEMBL2747422

SCHEMBL2747422

Nc1ncc(-c2cccc(C(=O)O)c2)cc1-c1nc2ccccc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.58
KDM4E B2RXH2 4/20 0.49
NFKB1 P19838 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MKNK1 Q9BUB5 2/20 0.48
POLB P06746 2/20 0.48
CDK1 P06493 1/20 0.48
CDK2 P24941 1/20 0.48
MKNK2 Q9HBH9 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN5 P54829 1/20 0.48
PTPN11 Q06124 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
LDHA P00338 3/20 0.48
LDHB P07195 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750253 0.92 FYN (0.54) MAP4K4KDM4ENFKB1NFKB2RELA
SCHEMBL2748849 0.89 CDK8 (0.50) MAP4K4KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL2749378 0.89 MAP4K4 (0.65) MAP4K4KDM4ENFKB1NFKB2RELA
SCHEMBL2748893 0.89 MKNK2 (0.64) MAP4K4KDM4ENFKB1NFKB2RELA
SCHEMBL2747417 0.89 CDK8 (0.49) MAP4K4KDM4ESMN1; SMN2MKNK1POLB
SCHEMBL2749700 0.86 ATR (0.52) MAP4K4LMNAATRALDH1A1FYN
SCHEMBL2749502 0.86 BCL2 (0.48) MAP4K4KDM4ENFKB1NFKB2RELA
SCHEMBL2750571 0.85 ATR (0.51) MAP4K4SMN1; SMN2MEN1KMT2AATR
SCHEMBL2748643 0.85 RAB9A (0.64) KDM4ENFKB1NFKB2RELASMN1; SMN2
SCHEMBL2750173 0.84 MAP4K4 (0.56) MAP4K4KDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MAP4K4 164/4885KDM4E 1371/4885NFKB1 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.